Cardiac disease is the primary cause of death in sickle cell disease (SCD). Right and left ventricular global longitudinal strain (RVGLS, LVGLS) are early markers of systolic dysfunction but are not well investigated among children with SCD. One hundred and forty-three patients with HbSS or HbSb 0 -thalassaemia (median age 11 years, range 5-19 years) and 71 controls matched for age and sex were compared. RVGLS and LVGLS were measured and compared with conventional measures of echocardiography and markers of haemolysis and inflammation. RVGLS was higher in children with SCD than in controls (À25Á72% AE 3Á45% vs. À24Á54%-AE 2Á41%, P = 0Á005); LVGLS was not different. RVGLS decreased with older age in children with SCD (q = 0Á338, P < 0Á001) but not among controls. Decreased RVGLS was associated with increased left atrial end diastolic volume (q = 0Á181, P = 0Á04); RVGLS increased with cardiac output (r = À0Á279, P = 0Á01). RVGLS and LVGLS were not associated with disease-modifying therapies, degree of anaemia or haemolysis markers. Elevated RVGLS may indicate an early RV compensatory mechanism in response to upstream myocardial insults and elevated cardiac output. Global longitudinal strain may serve as an early marker of altered myocardial function in children with SCD.
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Sickle cell disease (SCD) is an inherited haemoglobinopathy and multisystem disease causing acute (e.g., pain, stroke) and chronic (e.g., nephropathy, cardiomyopathy) complications (Voskaridou et al, 2012; Heeney & Ware, 2015) . Cardiopulmonary complications represent the most common causes of death in adults with SCD; however, understanding of cardiac pathophysiology is limited (Fitzhugh et al, 2010; Hamideh & Alvarez, 2013) . Chronic anaemia in SCD leads to elevated cardiac output and subsequent increased left ventricular (LV) mass with preserved systolic function (ejection fraction, EF) early in life (Gladwin et al, 2004; Sachdev et al, 2007; Voskaridou et al, 2012) . LV diastolic dysfunction and tricuspid regurgitant velocity (TRV) elevation are both risk factors for premature death in adults (Gladwin et al, 2004; Sachdev et al, 2007) . The precise sequence of dysfunctional events that culminates in cardiac disease is still being defined.
Myocardial global longitudinal strain (GLS) measures systolic function of both the right ventricle (RVGLS) and left ventricle (LVGLS) by evaluating myocardial tissue deformation (i.e., lengthening, shortening and thickening) via speckle-tracking echocardiography. Speckle tracking is an echocardiographic imaging technique that quantitatively evaluates myocardial tissue deformation by tracking a multitude of individual ultrasound reflection points (speckles) within the myocardium during the cardiac cycle (Gorcsan & Tanaka, 2011) . Evaluation of GLS enables the assessment of clinical and subclinical changes in ventricular systolic function that may be undetectable when using conventional echocardiographic measures, such as EF. Consequently, GLS is a marker of early cardiac disease with important prognostic value and clinical relevance (Cho et al, 2009; Stanton et al, 2009; Kalam et al, 2014; Armstrong et al, 2015) . LVGLS can identify systolic dysfunction before EF decreases and is a predictor of early adverse cardiac events (Cho et al, 2009; Kalam et al, 2014) . Abnormal RVGLS is associated with adverse clinical events and death in patients with research paper First published online 19 November 2018 doi: 10.1111/bjh.15607 underlying cardiopulmonary disease (Cameli et al, 2013; Nagy et al, 2015) .
GLS is insufficiently investigated in patients with SCD, especially among children. We hypothesized that GLS is lower in children with SCD compared with non-SCD children and that it is associated with biomarkers of disease severity. We compared RVGLS and LVGLS between children with SCD and controls and investigated their association with biomarkers of haemolysis and inflammation as well as other echocardiographic measures. We explored the potential effect of disease-modifying therapy on LVGLS and RVGLS.
Methods

Study population
Children with SCD were selected from a single-institution prospective cohort study (NCT00842621) that investigated cardiac abnormalities in 5-to 19-year-old children with SCD. Only participants with HbSS and HbSb 0 -thalassaemia without a history of previous cardiac surgery, LV shortening fraction <28%, or structural heart defects were included. Subjects with SCD were categorized into 3 sub-groups according to disease-modifying treatment exposure: untreated, hydroxycarbamide therapy-treated, and chronic transfusion therapy-treated (i.e., patients treated with monthly simple transfusions). We recruited 71 controls who were frequency-matched for age and sex (one control per two patients) (Rothman et al, 2008) . Inclusion criteria included normal physical examination and echocardiogram evaluation and absence of genetic syndromes and chronic disease. The institutional review board approved this study. Informed consent was obtained from legal guardians, and assent was obtained from participants aged 14 years or older.
Study evaluations
Participants with SCD underwent echocardiography evaluation at 30 or more days following acute events. The following assessments occurred on the same day of echocardiography: measurement of systolic and diastolic blood pressure, heart rate, body surface area, haemoglobin (Hb) concentration, white blood cell (WBC) count, absolute reticulocyte count, platelet count, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), fractionated bilirubin, N-terminal pro-brain natriuretic peptide (NT-pro-BNP), C-reactive protein (CRP), interleukin-6 (IL6), and von Willebrand factor antigen.
Echocardiography
Complete, 2-dimensional transthoracic echocardiograms were obtained by using Vivid 7 or E9 ultrasound systems (GE Medical Systems, Milwaukee, WI, USA). All measurements were performed according to American Society of Echocardiography guidelines (Lang et al, 2015) . Two cardiologists centrally read all echocardiograms: one for children with SCD and one for controls. M-mode analysis was performed from a parasternal long-axis projection of the left ventricle. Colour flow, spectral and tissue Doppler measurements were obtained. Normative data for diastolic function were derived from the general paediatric population (Eidem et al, 2004) .
To evaluate myocardial strain, speckle tracking-based GLS analysis was performed for the left ventricle by using an 18-segment method and for the right ventricle by using a 6-segment method (free wall and septum). LVGLS was obtained by averaging 6 segments from the apical four-chamber, twochamber, and three-chamber LV views. RVGLS was obtained by averaging six segments from the apical four-chamber RV view. Standard, commercially available software modified for application to the right ventricle was used (EchoPAC-PC BT10 or BT12; GE Medical Systems, Horten, Norway). GLS is reported in negative percentage values, with larger absolute values denoting increased (enhanced) myocardial deformability.
Measurements of LV mass, dimension, and systolic function were made by using M-mode data. Cardiac output (cardiac index) was determined by using LV outflow tract dimensions and velocity-time integral technique. Tricuspid annular plane systolic excursion (TAPSE) was measured in the four-chamber view by using M-mode data. TAPSE measures right ventricle base-to-apex shortening during systole and correlates closely with RVEF (Lang et al, 2015) . Left atrial (LA) volume was measured at end systole using the area-length method of disks measured from both the apical four-and two-chamber views and indexed to body surface area (Lang et al, 2015) . Elevated TRV was defined as ≥2Á5 m/ s on Doppler ultrasound. Early mitral and tricuspid flow velocity (E) and mitral and tricuspid annular (lateral) velocities (e 0 ) were measured by using spectral and tissue Doppler imaging, respectively. E/e 0 and E/A ratios were calculated in EchoPAC software.
Statistical analyses
Subjects with SCD were categorized into 3 sub-groups according to disease-modifying treatment exposure: untreated, hydroxycarbamide therapy-treated, and chronic transfusion therapy-treated. Univariate linear regression analysis was performed to test associations between GLS and covariates. Covariates associated with the outcomes in the univariate analyses at a nominal level of 0Á1 were further investigated in a multivariate linear regression model based on a model selection strategy. To avoid collinearity, we included only age at echocardiogram evaluation instead of body surface area and e 0 instead of E or E/e 0 in the multivariate model selection. Normality of continuous variables was assessed by using the Shapiro-Wilk test. Sensitivity analyses were performed to assess the robustness of the results. The Benjamini-Hochberg method was used to adjust for multiple comparisons among multiple groups to control a false discovery rate at 0Á05 (Benjamini & Hochberg, 1995) . Otherwise, P < 0Á05 were considered to be statistically significant. Statistical analyses were performed by using SAS software, version 9.3 (SAS Institute, Cary, NC) and R-3.2.5 (R Core Team, Vienna, Austria).
Reproducibility of echocardiogram findings
The Bland-Altman method was used to investigate the interobserver variability between the two cardiologists' echocardiogram measurements of RVGLS and LVLGS for the SCD and control groups (Altman & Bland, 1983; Bland & Altman, 1986) . Ten participants from both the SCD and control groups were randomly selected, including from all 3 treatment subgroups. In patients with SCD, the mean difference was 0Á01 AE 0Á73 [95% confidence interval (CI): À1Á5 to 1Á5] for LVGLS and 0Á01 AE 1Á53 (95% CI: À3Á1 to 3Á1) for RVGLS. In controls, the mean difference was 0Á3 AE 0Á71 (95% CI: À1Á1 to 1Á7) for LVGLS and 0Á12 AE 0Á68 (95% CI: À1Á2 to 1Á5) for RVGLS (Fig 1) . The bias between examiners was minimal in both groups (mean difference ≤0Á3). Lin's concordance correlation coefficient was determined and demonstrated high levels of agreement (Appendix S1) (Lin, 1989) .
Results
Patient characteristics
A total of 143 participants underwent GLS evaluation: 133 with HbSS and 10 with HbSb 0 -thalassaemia. All patients were non-Hispanic African American. Their mean age was 12Á47 AE 3Á76 years (median, 11Á75; range 5Á69-19Á62 years); 75 (52%) were girls and 68 (48%) boys. At the time of evaluation, 78 (55%) participants were receiving hydroxycarbamide therapy and 14 (10%) were receiving chronic transfusion therapy. Participants in the 3 SCD treatment subgroups were similar except that untreated children were younger and had lower body surface area than did those in either of the treatment groups (Table I) .
Seventy-one controls were included; 49 (69%) were nonHispanic African American and 22 (31%) were Caucasian. No echocardiographic differences were found between race or ethnicity, so all controls were combined into a single group. Children with SCD had lower body surface area and diastolic blood pressure and higher heart rates and systolic blood pressure than did controls (Table I) .
Global longitudinal strain in SCD
Contrary to our hypothesis, RVGLS was increased in children with SCD compared with controls (À25Á72% AE 3Á45% vs. À24Á54% AE 2Á41%, P = 0Á005), although LVGLS was similar in both groups (Table II, Fig 2A) . RVGLS (but not LVGLS) decreased with older age in children with SCD (q = 0Á338, P < 0Á001) (Table III, Fig 2B) but not among controls.
To assess the relationship of myocardial strain with traditional measures of ventricular systolic function in children with SCD, we investigated the association of LVGLS and RVGLS with LVEF and TAPSE. LVEF and TAPSE were both normal and not different among patients and controls (Table II) . GLS and classic measures of ventricular systolic function were concordant: decreased LVGLS and RVGLS were associated with both decreased LVEF (r = À0Á411, P < 0Á001 and r = À0Á22, P = 0Á01, respectively) and decreased TAPSE (r = À0Á333, P < 0Á001 and r = À0Á283, P = 0Á001, respectively). Because cardiac output is increased in SCD, we assessed the relationship between myocardial strain and cardiac index. Increased RVGLS (but not LVGLS) was associated with increased cardiac index (r = À0Á279, P = 0Á01) (Table III) .
Global longitudinal strain association with diastolic function and LA volume
Compared with normal reference values (Eidem et al, 2004) , MV e 0 and TV e 0 were abnormally low in 54 (38%) and 75 (54%) of patients with SCD, respectively. MV E/e 0 and TV E/e 0 ratios were higher than the normal reference for age in 80 (57%) and 95 (69%) of patients with SCD, respectively (Table IV) . Decreased MV e 0 and TV e 0 measurements were associated with decreased LVGLS (r = À0Á366, P < 0Á001, and r = À0Á17, P = 0Á04, respectively) and decreased RVGLS (r = À0Á196, P = 0Á03 and r = À0Á274, P = 0Á002, respectively) (Table III) . In controls, decreased TV e 0 measurements were associated with decreased RVGLS (q = À0Á359, P = 0Á002). These findings suggest that the increased prevalence of diastolic dysfunction in children with SCD reduces myocardial deformability, as measured by myocardial strain. Left atrial end diastolic volume (LAEDV) and RVGLS were associated (q = 0Á181, P = 0Á04), (Table III, Fig 2C) , reflecting enhanced RVGLS in response to an enlarging LA. Increased LA end systolic volume was associated with decreased LVGLS (q = 0Á212, P = 0Á012; Table III ), probably reflecting an early decline in LV systolic function with an enlarging LA. Data are expressed as mean AE SD. There is no difference for all variables between hydroxycarbamide-treated SCD and chronic transfusion-treated SCD. BSA, body surface area; DBP, diastolic blood pressure; FDR, false discovery rate; SBP, systolic blood pressure; SCD, sickle cell disease. *FDR corrected P < 0Á05 for the comparison between SCD (all groups) and controls. †FDR corrected P < 0Á05 for the comparison between untreated and hydroxycarbamide-treated SCD. ‡FDR corrected P < 0Á05 for the comparison between untreated and chronic transfusion-treated SCD.
Global longitudinal strain association with TRV
A TRV measurement of ≥2Á5 m/s was seen in 30 (23%) children with SCD (two of which had a TRV >3Á0 m/s), which was higher than that in controls (Table II) . LVGLS and RVGLS in patients with SCD did not differ between TRV groups dichotomized at 2Á5 m/s. TRV as a continuous variable was weakly associated with increased LVGLS for all patients with SCD (r = À0Á175, P = 0Á047) but not with RVGLS. When assessed by treatment group, only chronic transfusion therapyÀtreated patients maintained the association between TRV and LVGLS (r = À0Á62, P = 0Á02), and TRV was also associated with increased RVGLS in this group (r = À0Á58, P = 0Á038) (Table III) . Cardiac index and TRV were not associated.
Global longitudinal strain association with disease-modifying therapies and disease biomarkers
Increased markers of haemolysis (LDH, q = À0Á178, P = 0Á045), inflammation (WBC count, q = À0Á282, P = 0Á001) and myocardial function (NT-pro-BNP, q = À0Á197, P = 0Á025) were associated with increased RVGLS (Table III ). An increased CRP (inflammatory marker) was associated with decreased LVGLS (q = 0Á252, P = 0Á003), while an increased NT-pro-BNP was associated with increased LVGLS (q = À0Á247, P = 0Á003 (Table III) . IL6, a pro-inflammatory cytokine, was measured in 142 of the 143 patients and was below the limit of detection (10Á3 pg/ml) in 113 participants. In the remaining 29 participants, IL6 was not significantly associated with LVGLS, RVGLS, or CRP. The number of lifetime vaso-occlusive crises (verified by medical record review) did not associate with GLS, even in analyses stratified by age.
In multivariate linear regression analysis, factors that remained independently associated with RVGLS were age (b = 0Á281, P < 0Á001), WBC count (b = À0Á236, P < 0Á01), TAPSE (b = À2Á46, P < 0Á001), LAEDV (b = 0Á106, P = 0Á02) and TV e 0 (b = À19Á1, P = 0Á04). Factors that remained independently associated with LVGLS were LVEF (b = À0Á13, P < 0Á001), TAPSE (b = À1Á14, P < 0Á01), and MV e 0 (b = À14Á5, P < 0Á01). Treatment with hydroxycarbamide or chronic transfusions and haemolysis markers (Hb, LDH, AST and indirect bilirubin levels) were not associated with RVGLS or LVGLS.
Ten of the 14 chronic transfusion therapy-treated patients had myocardial tissue iron deposition quantified using magnetic resonance imaging T2*, and none demonstrated an abnormal value (<20 ms). Additionally, there was no correlation between serum ferritin level and RVGLS or LVGLS (77) 67 (94) 34 (72) 57 (83) 8 (62) * TRV ≥2Á5 n, (%) 30 (23) 4 (6) 13 (28) 12 (17) 5 (38)
Data are expressed as mean AE SD. There is no difference for all variables between untreated or hydroxycarbamide-treated SCD and chronic transfusion-treated SCD. CI, cardiac index; E, early flow velocity; e 0 , annular velocity; FDR, false discovery rate; LAEDV, left atrial end-diastolic volume; LAESV, left atrial end-systolic volume; LVEF, left ventricular ejection fraction; LVGLS, left ventricular global longitudinal strain; MV, mitral valve; RVGLS, right ventricular global longitudinal strain; SCD, sickle cell disease; TAPSE, tricuspid annular plane systolic excursion; TRV, tricuspid regurgitant velocity; TV, tricuspid valve. *FDR corrected P < 0Á05 for the comparison between SCD (all groups) and controls. †FDR corrected P < 0Á05 for the comparison between untreated and hydroxycarbamide-treated SCD.
among these 14 patients. To determine whether the cardiovascular physiology of chronic transfusion therapyÀtreated patients created an inhomogeneous study population, we repeated multivariate linear regression analyses after excluding this subset of patients. Associations with RVGLS were unchanged. Age was associated with LVGLS (b = 0Á102, P = 0Á031) while MV e 0 was no longer associated with LVGLS (b = À9Á37, P = 0Á066).
Discussion
Cardiac complications in SCD are insufficiently understood or surveilled, despite accounting for approximately 30% of deaths among adults (Fitzhugh et al, 2010; Hamideh & Alvarez, 2013) . GLS is an early marker of myocardial contractile dysfunction, but there is limited information on its significance in individuals with SCD. In our study, RVGLS was mildly but significantly increased in children with SCD compared with controls, despite normal RV systolic function (TAPSE). RVGLS increased with cardiac output; was independent of haemolysis and elevated TRV; and decreased with age, LA dilation, and diastolic dysfunction. LVGLS was not different between patients and controls. Neither RVGLS nor LVGLS were altered by exposure to hydroxycarbamide or chronic transfusions. The increased RVGLS points to an early compensatory mechanism of the right ventricle in response to upstream myocardial insults as well as elevated cardiac output. Cardiac abnormalities in SCD begin in early childhood, progress throughout adulthood, and culminate in significant morbidity and mortality, including arrhythmia and sudden cardiac death (Manci et al, 2003; Sachdev et al, 2007; Fitzhugh et al, 2010; Hamideh & Alvarez, 2013) . A model for the progression of myocardial dysfunction was recently proposed. This model purports an intrinsic cardiomyopathy with features of both restrictive physiology and anaemiainduced hyperdynamic physiology, characterized by LV diastolic dysfunction, LA dilation, mild secondary pulmonary venous hypertension and normal LV systolic function Niss et al, 2016) . Our finding of enhanced RVGLS with progressive increase in LAEDV may represent an additional pathophysiological step within this model. Increased RVGLS may represent an early enhancement of cardiac systolic function as a compensatory response to preceding insults to the myocardium and increased cardiac output. The upstream inciting events include left ventricle hypertrophy secondary to both a high-cardiac output state from chronic anaemia and to diastolic dysfunction. Diastolic dysfunction may result from a combination of myocardial fibrosis, microvascular occlusions by sickle cells, ischaemic events, cardiomyocyte loss, and oxidative stress (Parent et al, 2011; Fonseca et al, 2012; Bakeer et al, 2016; Niss et al, 2016 Niss et al, , 2017 ). These progressive myocardial insults then promote LA dilation, increased LA pressure, and a mild retrograde increase in pulmonary venous pressure , which may ultimately lead to a compensatory increase in RVGLS. This compensatory mechanism may be an early echocardiography-measurable indicator of pathological change in RV systolic function. This effect may be lost as patients age, as suggested by the decrease in RVGLS with aging ( Fig 2B) . The lack of association between RVGLS and TRV in our population does not exclude pulmonary pressure elevation as an intermediate step between increasing LA volume and increased RVGLS. TRV elevation >2Á5 m/s has a low sensitivity and specificity of 78% and 19%, respectively, for pulmonary hypertension (Parent et al, 2011; Fitzgerald et al, 2012) . Pulmonary capillary wedge pressure, obtained by right heart catheterization, is the optimal approach for detecting elevated pulmonary arterial and venous pressure, but given its risks, it was not performed in this cohort (Parent et al, 2011; Fonseca et al, 2012) . Other studies have also observed LA dilation, LV diastolic dysfunction, and abnormal RV structure and function in patients with SCD, often independent of elevated TRV (Knight-Perry et al, 2011; Junqueira et al, 2013; Bakeer et al, 2016; Niss et al, 2016) .
Similar to what is seen in other organs, an increase in RVGLS during childhood may be another compensatory singularity in SCD. Sickle nephropathy, for instance, is characterized by compensatory glomerular enlargement and hyperfiltration in infancy (Ware et al, 2010) . Additionally, a 
Results presented as correlation coefficients. An inverse correlation (negative correlation coefficient) denotes increased strain values with increasing values of the variable, whereas a direct correlation (positive correlation coefficient) denotes decreased strain values with increasing values of the variable. ARC, absolute reticulocyte count; AST, aspartate aminotransferase; BSA, body surface area; CI, cardiac index; CRP, C-reactive protein; E, early flow velocity; e 0 , annular velocity; LAEDV, left atrial end-diastolic volume; LAESV, left atrial end-systolic volume; LDH, lactate dehydrogenase; LVEF, left ventricular ejection fraction; LVGLS, left ventricular global longitudinal strain; MV, mitral valve; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; RVGLS, right ventricular global longitudinal strain; SCD, sickle cell disease; TAPSE, tricuspid annular plane systolic excursion; TRV, tricuspid regurgitant velocity; TV, tricuspid valve; VWF, von Willebrand factor; WBC, white blood cell. *P < 0Á05; †P < 0Á01; ‡P < 0Á001.
compensatory increase in cerebral blood flow occurs in SCD due to chronic anaemia and insufficient oxygen tissue delivery (Jordan & DeBaun, 2017) . Although LV diastolic dysfunction is not always responsible for the magnitude of observed LA dilation in patients with SCD, the degree of LA enlargement typically observed cannot be explained by an anaemia-induced high-cardiac output state alone, as supported by a lack of association between cardiac index and LAEDV (Hammoudi et al, 2015; Niss et al, 2016) . However, hyperdynamic physiology does appear to contribute to an increased RVGLS, as supported by the association of RVGLS with cardiac index and inflammatory and haemolytic biomarkers. TAPSE and cardiac index were not associated, further suggesting that RVGLS may be an earlier marker of RV systolic change than TAPSE in patients with SCD. The increase in RVGLS did not associate with the number of lifetime vaso-occlusive events experienced, demonstrating that cardiac abnormalities may occur in the absence of classical markers of disease severity. This is the largest of only 8 studies to evaluate GLS in SCD and the third to evaluate it in children (Almeida et al, 2008; Ahmad et al, 2012; Blanc et al, 2012; Sengupta et al, 2012; Barbosa et al, 2014; Hammoudi et al, 2014; Braga et al, 2015; Tolba et al, 2017) . In the two other paediatric studies to date, RVGLS was reported to be decreased in children compared with controls, but differences in evaluation technique or patient population may account for these discrepancies (Blanc et al, 2012; Tolba et al, 2017) . Blanc et al (2012) evaluated 28 children and reported that RVGLS was decreased compared with controls (À28Á5% AE 5Á6% vs. À34Á1% AE 5Á0%, P = 0Á0003). Similarly, Tolba et al (2017) evaluated 30 children and reported that RV peak longitudinal systolic strain was decreased compared with controls (À14Á7% AE 4Á3% vs. À18Á1% AE 2Á0%, P = 0Á009). In both of these studies, the discrepancy may be partly due to systematic ascertainment differences. Whereas we calculated RVGLS using the average of the RV free wall and septal segments (six segments), Blanc et al (2012) and Tolba et al (2017) used only the free wall (3 segments). Accuracy of RV measurements may be limited when the RV free wall is not well defined due to its complex structure and retrosternal position, and measurement of only the free wall may not provide the global estimate of RV systolic function. Although no consensus exists at this time, measuring 6 segments may provide a more complete and accurate method for assessing RVGLS (Lang et al, 2015) . In addition, Tolba et al (2017) reported a mean age of 30Á6 months and a mean Hb concentration of 71 g/l for children with SCD, both of which are much lower than in our study and may have influenced results.
GLS has been evaluated in young adults with SCD (mean age 23Á5-25 years), and no significant difference in RVGLS or LVGLS was observed when compared with controls (Barbosa et al, 2014; Braga et al, 2015) . Following an early compensatory enhanced RV systolic function in childhood (manifested by increased RVGLS), RVGLS may normalize in young adulthood and later decline. The right ventricle, not designed for pumping against elevated pressure or in a persistently hyperdynamic environment, cannot sustain prolonged enhanced function and probably experiences a mechanical tiring out, resulting in an eventual decline in RV systolic function in later adulthood (Knight-Perry et al, 2011; Junqueira et al, 2013) . Because GLS has not been reported in patients with SCD beyond young adulthood (Barbosa et al, 2014; Braga et al, 2015) , we cannot yet affirm if the early compensatory increase in RVGLS ultimately diminishes to abnormal levels in later adulthood, similar to the observed renal trajectory of early glomerular hyperfiltration in childhood with later decline (Ware et al, 2010) . The association of increased WBC count, NT-pro-BNP, and LDH with enhanced RVGLS is probably a reflection of the underlying pathophysiology of SCD, in which greater inflammation and haemolysis contribute to a hyperdynamic cardiac state. In adults with SCD, elevated NT-pro-BNP is associated with increased TRV and is an independent predictor of mortality (Machado et al, 2006) . Similarly, elevated CRP is associated with early death in adults with SCD (van Beers et al, 2015) . Although CRP and plasma levels of IL6 have been correlated in adults with SCD, they were not associated in our analysis of children with SCD, nor were they associated with GLS. This lack of association may reflect exposure to disease-modifying therapy, small sample size, or a lesser degree of disease severity compared with adults with SCD. Investigation of inflammatory markers is warranted given the recent observation that a decline of IL6 is associated with reduction of cardiac hypertrophy in a mouse model of SCD (Sparkenbaugh et al, 2016) .
Study limitations
Although our study contains the largest cohort of individuals with SCD in which GLS was evaluated, limitations should be considered. Our study was a cross-sectional analysis without randomization to different therapies and did not include adults. We did not directly measure pulmonary hypertension by right heart catheterization given its risks in asymptomatic children. Our results should be confirmed in prospective longitudinal trials of children and adults with SCD; inclusion of additional echocardiographic preload measures (e.g., left and right ventricular volumes and inferior vena cava size) and direct pulmonary pressure evaluation may be warranted.
Conclusions
RVGLS was higher in children with SCD than in controls, paralleled elevation in cardiac output, decreased with age, and was independent of haemolysis and elevated TRV.
RVGLS was associated with diastolic dysfunction and LA dilation and may represent an additional step in the recently proposed pathophysiological model of sickle cardiomyopathy with restrictive physiology. Evaluation of GLS by speckletracking echocardiography may reveal subclinical changes in cardiac function and identify opportunities for early medical interventions or increased surveillance in patients with SCD. Although disease-modifying therapies did not alter the effects of SCD on GLS in our study population, longitudinal studies are necessary to confirm this finding. Long-term follow-up of patients with SCD is needed to determine whether GLS may be used as an early marker of altered myocardial function in SCD.
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